{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:13:36Z","timestamp":1789773216261,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,23]]},"DOI":"10.7759\/cureus.27170","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T14:16:47Z","timestamp":1658585807000},"source":"Crossref","is-referenced-by-count":4,"title":["Dupilumab-Associated Head and Neck Dermatitis With Ocular Involvement in a Ten-Year-Old With Atopic Dermatitis: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Arthur M","family":"Samia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyda","family":"Cuervo-Pardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie E","family":"Montanez-Wiscovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa  Y","family":"Cavero-Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger S","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016, 387:1109-22. 10.1016\/S0140-6736(15)00149-X","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000370220","article-title":"Atopic dermatitis: global epidemiology and risk factors","volume":"66","author":"Nutten S","year":"2015","unstructured":"Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015, 66:8-16. 10.1159\/000370220","journal-title":"Ann Nutr Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield LF","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG, et al.. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014, 71:116-32. 10.1016\/j.jaad.2014.03.023","journal-title":"J Am Acad Dermatol"},{"key":"ref4","article-title":"Post Hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis: Associated pruritus from phase 1 and 2 clinical studies","volume":"15","author":"Draelos ZD","year":"2016","unstructured":"Draelos ZD, Stein Gold LF, Murrell DF, Hughes MH, Zane LT. Post Hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis: Associated pruritus from phase 1 and 2 clinical studies. J Drugs Dermatology. 2016, 15:172-6.","journal-title":"J Drugs Dermatology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp K","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, et al.. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021, 85:863-72. 10.1016\/j.jaad.2021.04.085","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419882647","article-title":"Approach to the assessment and management of pediatric patients with atopic dermatitis: a consensus document. Section III: treatment options for pediatric atopic dermatitis","volume":"23","author":"Lansang P","year":"2019","unstructured":"Lansang P, Lam JM, Marcoux D, Prajapati VH, Spring S, Lara-Corrales I. Approach to the assessment and management of pediatric patients with atopic dermatitis: a consensus document. Section III: treatment options for pediatric atopic dermatitis. J Cutan Med Surg. 2019, 23:19-31. 10.1177\/1203475419882647","journal-title":"J Cutan Med Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1104a145","article-title":"Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib","volume":"11","author":"Nogueira M","year":"2021","unstructured":"Nogueira M, Torres T. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol Pract Concept. 2021, 11:e2021145. 10.5826\/dpc.1104a145","journal-title":"Dermatol Pract Concept"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14499","article-title":"New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis","volume":"38","author":"Bax CE","year":"2021","unstructured":"Bax CE, Khurana MC, Treat JR, Castelo-Soccio L, Rubin AI, McMahon PJ. New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis. Pediatr Dermatol. 2021, 38:390-4. 10.1111\/pde.14499","journal-title":"Pediatr Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson EL","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al.. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016, 375:2335-48. 10.1056\/NEJMoa1610020","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran M","year":"2020","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, et al.. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020, 82:377-88. 10.1016\/j.jaad.2019.07.074","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.08.016","article-title":"New treatments in atopic dermatitis","volume":"126","author":"Puar N","year":"2021","unstructured":"Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021, 126:21-31. 10.1016\/j.anai.2020.08.016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.1003","article-title":"Characterizing dupilumab facial redness in children and adolescents: a single-institution retrospective chart review","volume":"83","author":"Muzumdar S","year":"2020","unstructured":"Muzumdar S, Zubkov M, Waldman R, DeWane ME, Wu R, Grant-Kels JM. Characterizing dupilumab facial redness in children and adolescents: a single-institution retrospective chart review. J Am Acad Dermatol. 2020, 83:1520-1. 10.1016\/j.jaad.2020.06.1003","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.026","article-title":"Characterizing dupilumab facial redness: a multi-institution retrospective medical record review","volume":"82","author":"Waldman RA","year":"2020","unstructured":"Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020, 82:230-2. 10.1016\/j.jaad.2019.06.026","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.010","article-title":"Off-label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review","volume":"82","author":"Igelman S","year":"2020","unstructured":"Igelman S, Kurta AO, Sheikh U, et al.. Off-label use of dupilumab for pediatric patients with atopic dermatitis: a multicenter retrospective review. J Am Acad Dermatol. 2020, 82:407-11. 10.1016\/j.jaad.2019.10.010","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000385","article-title":"Pediatric baseline batch test series: pediatric contact dermatitis workgroup","volume":"29","author":"Yu J","year":"2018","unstructured":"Yu J, Atwater AR, Brod B, et al.. Pediatric baseline batch test series: pediatric contact dermatitis workgroup. Dermatitis. 2018, 29:206-12. 10.1097\/DER.0000000000000385","journal-title":"Dermatitis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000726","article-title":"Patch testing during immunosuppressive therapy: a systematic review","volume":"32","author":"Mufti A","year":"2021","unstructured":"Mufti A, Lu JD, Sachdeva M, et al.. Patch testing during immunosuppressive therapy: a systematic review. Dermatitis. 2021, 32:365-74. 10.1097\/DER.0000000000000726","journal-title":"Dermatitis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.07.020","article-title":"Dupilumab facial redness: positive effect of itraconazole","volume":"5","author":"de Beer FS","year":"2019","unstructured":"de Beer FS, Bakker DS, Haeck I, Ariens L, van der Schaft J, van Dijk MR, de Bruin-Weller MS. Dupilumab facial redness: positive effect of itraconazole. JAAD Case Rep. 2019, 5:888-91. 10.1016\/j.jdcr.2019.07.020","journal-title":"JAAD Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16383","article-title":"Successful topical treatment with ketoconazole for facial rashes refractory to dupilumab in patients with atopic dermatitis: case reports","volume":"34","author":"Okiyama N","year":"2020","unstructured":"Okiyama N, Nakamura Y, Ishitsuka Y, et al.. Successful topical treatment with ketoconazole for facial rashes refractory to dupilumab in patients with atopic dermatitis: case reports. J Eur Acad Dermatol Venereol. 2020, 34:e474-6. 10.1111\/jdv.16383","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.012","article-title":"Facial and neck erythema associated with dupilumab treatment: A systematic review","volume":"84","author":"Jo CE","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: A systematic review. J Am Acad Dermatol. 2021, 84:1339-47. 10.1016\/j.jaad.2021.01.012","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21019","article-title":"Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study","volume":"186","author":"Kozera E","year":"2022","unstructured":"Kozera E, Stewart T, Gill K, De La Vega MA, Frew JW. Dupilumab-associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia-specific IgE: a multicentre, prospective cohort study. Br J Dermatol. 2022, 186:1050-2. 10.1111\/bjd.21019","journal-title":"Br J Dermatol"},{"key":"ref21","article-title":"Improving the management of seborrhoeic dermatitis.","volume":"258","author":"Ooi ET","year":"2014","unstructured":"Ooi ET, Tidman MJ. Improving the management of seborrhoeic dermatitis.. Practitioner. 2014, 258:23-6.","journal-title":"Practitioner"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0109","article-title":"Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab","volume":"155","author":"Zhu GA","year":"2019","unstructured":"Zhu GA, Chen JK, Chiou A, Ko J, Honari G. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019, 155:850-2. 10.1001\/jamadermatol.2019.0109","journal-title":"JAMA Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9041241","article-title":"Dupilumab for the treatment of atopic dermatitis in an Austrian cohort-real-life data shows rosacea-like folliculitis","volume":"9","author":"Quint T","year":"2020","unstructured":"Quint T, Brunner PM, Sinz C, et al.. Dupilumab for the treatment of atopic dermatitis in an Austrian cohort-real-life data shows rosacea-like folliculitis. J Clin Med. 2020, 9:1241. 10.3390\/jcm9041241","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/102708-dupilumab-associated-head-and-neck-dermatitis-with-ocular-involvement-in-a-ten-year-old-with-atopic-dermatitis-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:31Z","timestamp":1707507391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/102708-dupilumab-associated-head-and-neck-dermatitis-with-ocular-involvement-in-a-ten-year-old-with-atopic-dermatitis-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.27170","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,23]]}}}